$CCEL
CRYO CELL INTERNATIONAL INC

2019 Q4 Form 10-Q Financial Statement

#000119312519267766 Filed on October 15, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2018 Q3
Revenue $7.970M $8.223M $7.871M
YoY Change -7.26% 4.47% 14.14%
Cost Of Revenue $2.352M $2.589M $2.486M
YoY Change -12.06% 4.15% 25.72%
Gross Profit $5.618M $5.634M $5.385M
YoY Change -5.08% 4.62% 9.49%
Gross Profit Margin 70.49% 68.51% 68.41%
Selling, General & Admin $3.942M $3.557M $4.391M
YoY Change -4.32% -19.0% 27.91%
% of Gross Profit 70.16% 63.13% 81.53%
Research & Development $16.86K $2.440K $22.23K
YoY Change -37.37% -89.03% 9738.05%
% of Gross Profit 0.3% 0.04% 0.41%
Depreciation & Amortization $96.85K $96.16K $94.28K
YoY Change -6.02% 1.99% 57.13%
% of Gross Profit 1.72% 1.71% 1.75%
Operating Expenses $4.005M $3.559M $4.413M
YoY Change -4.68% -19.35% 28.55%
Operating Profit $1.613M $1.993M $920.1K
YoY Change -6.07% 116.61% -36.64%
Interest Expense -$351.6K $413.9K $410.4K
YoY Change -36.23% 0.87% 30.32%
% of Operating Profit -21.8% 20.77% 44.6%
Other Income/Expense, Net $30.14K -$378.1K -$372.1K
YoY Change -176.81% 1.61% 20.15%
Pretax Income $1.291M $1.615M $548.1K
YoY Change -16.24% 194.68% -52.03%
Income Tax $446.3K $498.7K $303.1K
% Of Pretax Income 34.56% 30.88% 55.3%
Net Earnings $845.0K $1.116M $245.0K
YoY Change -5.14% 355.65% -62.43%
Net Earnings / Revenue 10.6% 13.57% 3.11%
Basic Earnings Per Share $0.14 $0.03
Diluted Earnings Per Share $101.1K $0.13 $0.03
COMMON SHARES
Basic Shares Outstanding 7.803M 7.803M 7.695M
Diluted Shares Outstanding 8.445M 8.376M

Balance Sheet

Concept 2019 Q4 2019 Q3 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.445M $8.213M $7.990M
YoY Change 7.65% 2.8% 53.94%
Cash & Equivalents $6.541M $7.339M $7.040M
Short-Term Investments $904.1K $874.7K $949.8K
Other Short-Term Assets $260.4K $260.0K $209.2K
YoY Change 2.33% 24.27% 14.24%
Inventory $1.085M $1.032M $16.17M
Prepaid Expenses $500.3K $526.3K $597.0K
Receivables $6.097M $5.888M $5.513M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $15.39M $15.92M $30.48M
YoY Change 4.25% -47.77% 177.66%
LONG-TERM ASSETS
Property, Plant & Equipment $1.846M $1.769M $1.540M
YoY Change 23.64% 14.87% 73.28%
Goodwill $1.941M $1.941M $2.008M
YoY Change 0.0% -3.32%
Intangibles $1.249M $1.268M $1.368M
YoY Change -6.86% -7.3% 482.07%
Long-Term Investments $308.0K $308.0K $308.0K
YoY Change 0.0% 0.0%
Other Assets $25.65M $24.14M $10.63M
YoY Change -1.85% 127.06% 12.49%
Total Long-Term Assets $27.50M $25.91M $12.17M
YoY Change -2.23% 112.86% 17.71%
TOTAL ASSETS
Total Short-Term Assets $15.39M $15.92M $30.48M
Total Long-Term Assets $27.50M $25.91M $12.17M
Total Assets $42.89M $41.83M $42.65M
YoY Change 0.0% -1.93% 100.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.369M $1.013M $1.120M
YoY Change 8.52% -9.53% -17.86%
Accrued Expenses $2.085M $1.373M $2.483M
YoY Change -22.85% -44.72% 35.95%
Deferred Revenue $8.875M $8.781M
YoY Change 6.09%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $3.100M $3.100M
YoY Change 0.0% 0.0% 55.0%
Total Short-Term Liabilities $15.43M $14.27M $14.91M
YoY Change 0.0% -4.33% 18.39%
LONG-TERM LIABILITIES
Long-Term Debt $5.856M $6.605M $1.425M
YoY Change 310.96% 363.48% 0.0%
Other Long-Term Liabilities $34.41M $34.52M $37.59M
YoY Change -4.07% -8.15% 69.89%
Total Long-Term Liabilities $34.41M $34.52M $39.01M
YoY Change -7.73% -11.5% 65.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.43M $14.27M $14.91M
Total Long-Term Liabilities $34.41M $34.52M $39.01M
Total Liabilities $49.84M $48.79M $52.50M
YoY Change -2.84% -7.06% 51.2%
SHAREHOLDERS EQUITY
Retained Earnings -$22.44M -$23.29M -$26.22M
YoY Change -11.39% -11.18% 4.24%
Common Stock $36.05M $35.90M $35.50M
YoY Change 1.13% 1.13% 13.68%
Preferred Stock
YoY Change
Treasury Stock (at cost) $20.56M $19.57M $19.57M
YoY Change 5.07% 0.0% 0.0%
Treasury Stock Shares $6.094M $5.801M 5.801M shares
Shareholders Equity -$6.953M -$6.963M -$9.849M
YoY Change
Total Liabilities & Shareholders Equity $42.89M $41.83M $42.65M
YoY Change 1.17% -1.93% 100.08%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2018 Q3
OPERATING ACTIVITIES
Net Income $845.0K $1.116M $245.0K
YoY Change -5.14% 355.65% -62.43%
Depreciation, Depletion And Amortization $96.85K $96.16K $94.28K
YoY Change -6.02% 1.99% 57.13%
Cash From Operating Activities $1.199M $2.743M $2.769M
YoY Change 42.04% -0.96% 125.15%
INVESTING ACTIVITIES
Capital Expenditures -$155.0K -$98.47K -$158.3K
YoY Change 309.3% -37.8% 163.83%
Acquisitions
YoY Change
Other Investing Activities -$29.36K $1.000K -$10.60M
YoY Change -5.47% -100.01% 105851.9%
Cash From Investing Activities -$184.3K -$97.47K -$10.74M
YoY Change 167.4% -99.09% 17805.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.812M -1.775M 8.485M
YoY Change 2.1% -120.92% -807.08%
NET CHANGE
Cash From Operating Activities 1.199M 2.743M 2.769M
Cash From Investing Activities -184.3K -97.47K -10.74M
Cash From Financing Activities -1.812M -1.775M 8.485M
Net Change In Cash -797.7K 870.2K 510.8K
YoY Change -20.22% 70.35% -1802.73%
FREE CASH FLOW
Cash From Operating Activities $1.199M $2.743M $2.769M
Capital Expenditures -$155.0K -$98.47K -$158.3K
Free Cash Flow $1.354M $2.841M $2.928M
YoY Change 53.52% -2.95% 126.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1493401
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-08-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Trading Symbol
TradingSymbol
CCEL
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1769213
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7338789
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6040033
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
874691
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
875689
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
526288
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
461815
CY2019Q3 us-gaap Inventory Net
InventoryNet
1031845
CY2018Q4 us-gaap Inventory Net
InventoryNet
1260557
CY2019Q3 us-gaap Other Assets Current
OtherAssetsCurrent
259971
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
254465
CY2019Q3 us-gaap Assets Current
AssetsCurrent
15919740
CY2018Q4 us-gaap Assets Current
AssetsCurrent
14759894
CY2019Q3 us-gaap Liabilities
Liabilities
48791115
CY2018Q4 us-gaap Liabilities
Liabilities
51298441
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1013037
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1261653
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1372539
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2702788
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41827756
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42390143
CY2019Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1268400
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1341336
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14266805
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15429725
CY2019Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
3601697
CY2018Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
4282975
CY2019Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2018Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
1425000
CY2019Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34524310
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
35868716
CY2019Q3 us-gaap Goodwill
Goodwill
1941411
CY2018Q4 us-gaap Goodwill
Goodwill
1941411
CY2019Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
7562705
CY2018Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
7656897
CY2019Q3 ccel Deposits And Other Assets
DepositsAndOtherAssets
412287
CY2018Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
113888
CY2019Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24138803
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
26136848
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
135989
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
135964
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35761040
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35515382
CY2019Q3 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
19571113
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
340984
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23289275
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25329515
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2589335
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2486180
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7683853
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
47286
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5864826
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3556602
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4390614
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10949831
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11513190
CY2019Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
34649
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-636278
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2440
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22234
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13281
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64927
CY2018Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
52072
us-gaap Depreciation And Amortization
DepreciationAndAmortization
159600
us-gaap Depreciation And Amortization
DepreciationAndAmortization
124865
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
6230312
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
6951100
us-gaap Costs And Expenses
CostsAndExpenses
20503050
us-gaap Costs And Expenses
CostsAndExpenses
17567808
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
35868
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38300
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2014
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14520
CY2019Q3 us-gaap Interest Expense
InterestExpense
413942
CY2018Q3 us-gaap Interest Expense
InterestExpense
410366
us-gaap Interest Expense
InterestExpense
1245154
CY2019Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2535513
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2264848
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13598909
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13596409
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7803333
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7800833
us-gaap Interest Expense
InterestExpense
995437
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-378074
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-372066
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1243140
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-980917
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1615007
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
548056
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2100167
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2076078
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
498748
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
303072
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
654358
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3821660
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1516666
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5700
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
170925
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3319297
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7484959
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
507339
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
408297
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1116259
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
530239
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1445809
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1340327
us-gaap Profit Loss
ProfitLoss
1445809
us-gaap Profit Loss
ProfitLoss
-1745582
us-gaap Share Based Compensation
ShareBasedCompensation
239983
us-gaap Share Based Compensation
ShareBasedCompensation
323798
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
587716
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
539365
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
3117263
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
86014
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
79876
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
608537
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
805183
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
64473
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
156022
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-25265
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-182466
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
5506
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3066
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-30832
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-248616
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-808839
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1311841
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-99555
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2991800
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3496790
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5124394
CY2019Q3 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
-340984
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3324997
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
200000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-998
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
105186
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-506341
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11213483
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4489342
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6279154
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7039972
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-8093792
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-8908298
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1298756
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
760818
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5700
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-14100156
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3666005
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-12502896
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3670925
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
14174
CY2019Q3 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
10747
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-6963359
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
239983
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
55412
CY2018Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
285255
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
-9848500
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
323798
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
405255
us-gaap Net Income Loss
NetIncomeLoss
-1745582
CY2019Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
31674315
CY2019Q3 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
8781229
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2017Q2 ccel Reimbursement Of Personal Expenses
ReimbursementOfPersonalExpenses
10000
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
25216
CY2018Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
329231
CY2018Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
66533
CY2019Q3 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
23180
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
67668
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8223393
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7871222
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
23846357
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20624803
CY2019Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
383399
CY2018Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
329231
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5888156
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5867335
CY2019Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8781229
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8365284
CY2019Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
22893086
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20317231
CY2019Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1634000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1634000
CY2019Q3 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
453000
CY2018Q3 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
245000
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
587000
us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
3741000
us-gaap Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
2985000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q3 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
46000
CY2018Q3 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
58000
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
68000
us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
80000
ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
240000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
324000
CY2018Q3 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
37536
us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
12328
CY2019Q1 ccel Cumulative Effect Adjustment From Accumulated Other Comprehensive Income To Retained Earnings
CumulativeEffectAdjustmentFromAccumulatedOtherComprehensiveIncomeToRetainedEarnings
341000
CY2019Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
35000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-1000
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2019Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1993081
CY2019Q3 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
13677845
CY2018Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
16035873
CY2019Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1268400
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1341336
CY2019Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2018Q3 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q3 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
2
CY2019Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
7871222
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
22794591
CY2018Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
244984
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-3797189
CY2018Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.03
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.52
CY2018Q3 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.03
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
920122
CY2019Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
12646000
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
14775316
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2019Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
ccel Allocated Share Based Compensation Expenses Reversed
AllocatedShareBasedCompensationExpensesReversed
444000
ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod
30000
CY2019Q3 us-gaap Interest Expense
InterestExpense
413942
CY2018Q3 us-gaap Interest Expense
InterestExpense
410366
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
498748
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
303072
us-gaap Operating Income Loss
OperatingIncomeLoss
3343307
us-gaap Interest Expense
InterestExpense
1245154
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
654358
us-gaap Operating Income Loss
OperatingIncomeLoss
3056995
us-gaap Interest Expense
InterestExpense
995437
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3821660
CY2019Q3 us-gaap Assets
Assets
41827756
CY2018Q4 us-gaap Assets
Assets
42390143
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
2332763
CY2019Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
0
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
0
CY2019Q3 ccel Inventory Collection Kits
InventoryCollectionKits
39137
CY2018Q4 ccel Inventory Collection Kits
InventoryCollectionKits
19163
CY2019Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2018Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
73000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
49000
CY2019Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
548085
CY2019Q3 us-gaap Notes Payable
NotesPayable
9883433
CY2018Q4 us-gaap Notes Payable
NotesPayable
13208433
CY2019Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
178906
CY2017 ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cash Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCashPayments
444000
CY2019Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
5801086
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.30
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
19000
us-gaap Interest Expense Debt
InterestExpenseDebt
393254
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
264923
CY2019Q3 us-gaap Long Term Debt
LongTermDebt
9704527
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
12943510
CY2019Q3 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3100000
CY2019Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
6604527
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9843510
CY2019Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
162134
us-gaap Interest Expense Debt
InterestExpenseDebt
523818
CY2019Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
28014
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
86014
CY2019Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
190148
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
609832
CY2018Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
204609
CY2018Q3 ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
28337
ccel Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
79876
CY2018Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
232946
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
473130
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
1116259
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
244984
us-gaap Net Income Loss
NetIncomeLoss
1445809
us-gaap Net Income Loss
NetIncomeLoss
-1745582
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7803333
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7694662
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7802676
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7350868
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
641904
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
681013
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.14
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
627575
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8445237
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8375675
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8430251
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7350868
CY2019Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1103830
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y2M8D
CY2019Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
3.26
CY2019Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1004312
CY2019Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.83
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
40254
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
112465
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
53201
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.16
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
99518
ccel Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Shares Settled For Cash In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesSettledForCashInPeriod
30000
dei Security12b Title
Security12bTitle
Common Stock
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-153756
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
9000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
169300
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
20103661
us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
1405406
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
10500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.23
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product Warranty and Cryo-Cell Cares<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">TM</div> Program </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#160;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Effective June&#160;1, 2017, the Company increased the payment warranty to $100,000 to all new clients who choose the premium processing method, Prepacyte CB. Additionally, under the Cryo-Cell CaresTM program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. Upon the adoption of ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method, therefore, the transaction price does not reflect any expectation of service level credits&#160;at August&#160;31, 2019.&#160;At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7803333
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
304463
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
214275
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.52
dei Security Exchange Name
SecurityExchangeName
NONE
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms
The options were issued under the Company&#8217;s 2012 Stock Plan and will vest 1/3 upon grant, 1/3 on December&#160;1, 2018 and the remaining 1/3 on November&#160;30, 2019
ccel Description On Second Amendment To Employment Agreement
DescriptionOnSecondAmendmentToEmploymentAgreement
The Amendment provides for the grant of shares of the Company&#8217;s common stock based on certain performance measures being attained by the Company during fiscal year 2016 and fiscal year 2017. The Amendment states if Executive is employed by the Company on November 30, 2016 and November 30, 2017, then no later than February 28, 2017 and February 28, 2018, respectively, the Company will grant Executive up to 20,000 shares of restricted stock based on performance as set forth in the Amendment per each fiscal year.
ccel Types Of License Agreements
TypesOfLicenseAgreements
2
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL

Files In Submission

Name View Source Status
0001193125-19-267766-index-headers.html Edgar Link pending
0001193125-19-267766-index.html Edgar Link pending
0001193125-19-267766.txt Edgar Link pending
0001193125-19-267766-xbrl.zip Edgar Link pending
ccel-20190831.xml Edgar Link completed
ccel-20190831.xsd Edgar Link pending
ccel-20190831_cal.xml Edgar Link unprocessable
ccel-20190831_def.xml Edgar Link unprocessable
ccel-20190831_lab.xml Edgar Link unprocessable
ccel-20190831_pre.xml Edgar Link unprocessable
d781457d10q.htm Edgar Link pending
d781457dex311.htm Edgar Link pending
d781457dex312.htm Edgar Link pending
d781457dex313.htm Edgar Link pending
d781457dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending